99mTc-methionine scintimammography in the evaluation of breast cancer

Nucl Med Commun. 2009 May;30(5):338-42. doi: 10.1097/MNM.0b013e32832999dc.

Abstract

Objective: The diagnostic utility of a C-methionine scan has been established in breast cancer. We were able to radiolabel methionine with Tc at our institute. Thus, we undertook clinical trials to determine the role of Tc-methionine scans in the detection of breast cancer.

Methods: Scintimammography was performed in 47 female (median age 44 years, range 28-68 years) patients having palpable breast masses. All of them underwent ultrasound, mammography, fine-needle aspiration cytology, and Tc-methionine scintimammography before surgery. The final diagnosis was made after histopathological examination. Tc-methionine scintimammography was done after injecting 555 MBq of radiotracer intravenously. The results of scintimammography were compared with histopathology.

Results: The histopathological findings were malignant in 33 (70%) and benign in 14 (30%) cases. Scintimammography showed true-positive findings in 29 patients out of 33 cases of breast cancer. True-negative findings were found in 13 out of 14 patients having benign breast lesions. The sensitivity, specificity, and positive predictive value were found to be 87.8, 92.8, and 96.6% respectively.

Conclusion: Tc-methionine imaging can provide useful information with reasonably high sensitivity and specificity in evaluating patients having breast masses.

MeSH terms

  • Adult
  • Aged
  • Breast / diagnostic imaging
  • Breast / pathology
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / pathology
  • Carbon Radioisotopes
  • Female
  • Humans
  • Lymphatic Metastasis
  • Methionine* / pharmacokinetics
  • Middle Aged
  • Radionuclide Imaging
  • Radiopharmaceuticals* / pharmacokinetics
  • Sensitivity and Specificity
  • Technetium
  • Tissue Distribution
  • Whole Body Imaging

Substances

  • Carbon Radioisotopes
  • Radiopharmaceuticals
  • Technetium
  • Methionine